Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Joseph Malvehy
Based on 137 articles published since 2010
(Why 137 articles?)
||||

Between 2010 and 2020, J. Malvehy wrote the following 137 articles about Melanoma.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6
1 Guideline Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. 2012

Garbe, Claus / Peris, Ketty / Hauschild, Axel / Saiag, Philippe / Middleton, Mark / Spatz, Alan / Grob, Jean-Jacques / Malvehy, Josep / Newton-Bishop, Julia / Stratigos, Alexander / Pehamberger, Hubert / Eggermont, Alexander M / Anonymous220737 / Anonymous230737 / Anonymous240737. ·University Department of Dermatology, Tuebingen, Germany. claus.garbe@med.uni-tuebingen.de ·Eur J Cancer · Pubmed #22981501.

ABSTRACT: Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. Diagnosis is made clinically and staging is based upon the AJCC system. CMs are excised with one to two centimetre safety margins. Sentinel lymph node dissection (SLND) is routinely offered as a staging procedure in patients with tumours more than 1mm in thickness, although there is as yet no clear survival benefit for this approach. Interferon-α treatment may be offered to patients with stage II and III melanoma as an adjuvant therapy, as this treatment increases at least the disease-free survival (DFS) and less clear the overall survival (OS) time. The treatment is however associated with significant toxicity. In distant metastasis, all options of surgical therapy have to be considered thoroughly. In the absence of surgical options, systemic treatment is indicated. BRAF inhibitors like vemurafenib for BRAF mutated patients as well as the CTLA-4 antibody ipilimumab offer new therapeutic opportunities apart from conventional chemotherapy. Therapeutic decisions in stage IV patients should be primarily made by an interdisciplinary oncology team ('tumour board').

2 Guideline [Initial evaluation, diagnosis, staging, treatment, and follow-up of patients with primary cutaneous malignant melanoma. Consensus statement of the Network of Catalan and Balearic Melanoma Centers]. 2010

Mangas, C / Paradelo, C / Puig, S / Gallardo, F / Marcoval, J / Azon, A / Bartralot, R / Bel, S / Bigatà, X / Curcó, N / Dalmau, J / del Pozo, L J / Ferrándiz, C / Formigón, M / González, A / Just, M / Llambrich, A / Llistosella, E / Malvehy, J / Martí, R M / Nogués, M E / Pedragosa, R / Rocamora, V / Sàbat, M / Salleras, M. ·Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. cris_mangas@yahoo.es ·Actas Dermosifiliogr · Pubmed #20223155.

ABSTRACT: The consensus statement on the management of primary cutaneous melanoma that we present here was based on selection, discussion, review, and comparison of recent literature (including national and international guidelines). The protocols for the diagnosis, treatment, and follow-up used in the hospital centers throughout Catalonia and the Balearic Isles belonging to the Network of Catalan and Balearic Melanoma Centers were also considered. The main objective of this statement was to present the overall management of melanoma patients typically used in our region at the present time. As such, the statement was not designed to be an obligatory protocol for health professionals caring for this group of patients, and neither can it nor should it be used for this purpose. Professionals reading the statement should not therefore consider it binding on their practice, and in no case can this text be used to guarantee or seek responsibility for a given medical opinion. The group of dermatologists who have signed this statement was created 3 years ago with the aim of making our authorities aware of the importance of this complex tumor, which, in comparison with other types of cancer, we believe does not receive sufficient attention in Spain. In addition, the regular meetings of the group have produced interesting proposals for collaboration in various epidemiological, clinical, and basic applied research projects on the subject of malignant melanoma in our society.

3 Editorial Dermoscopy in Europe: coming of age. 2016

Bahadoran, P / Malvehy, J. ·Department of Dermatology, Clinical Research Center, Archet Hospital, Nice, France. · Dermatology Department, Melanoma Unit, Hospital Clinic and IDIBAPS, Barcelona, Spain. ·Br J Dermatol · Pubmed #27996126.

ABSTRACT: -- No abstract --

4 Review Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. 2018

Gutzmer, Ralf / Harrington, Kevin J / Hoeller, Christoph / Lebbé, Celeste / Malvehy, Josep / Öhrling, Katarina / Downey, Gerald / Dummer, Reinhard. ·Haut-Tumour-Zentrum Hannover (HTZH), Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover (MHH), Hannover, Germany. · NIHR Biomedical Research Centre, The Institute of Cancer Research, London, UK. · Universitätsklinik für Dermatologie, Medizinische Universität Wien, Wien, Austria. · APHP Dermatology and CIC department INSERM U976, Sorbonne Paris Cité, Université Paris Diderot, Hôpital Saint-Louis, Paris, France. · Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBER de Enfermedades Raras, FIS del Instituto de Salud Carlos III, Barcelona, Spain. · Medical Development, Amgen (Europe) GmbH, Rotkreuz, Switzerland. · Biostatistics, Amgen Ltd, Cambridge, UK. · Skin Cancer Centre/Dermatology Clinic, Universitätsspital Zürich, Zürich, Switzerland. ·Eur J Dermatol · Pubmed #30698145.

ABSTRACT: Talimogene laherparepvec, a herpes simplex virus type 1-based intralesional oncolytic immunotherapy, is approved in Europe for the treatment of adults with unresectable stage IIIB-IVM1a melanoma, with no bone, brain, lung or other visceral disease. It has direct oncolytic effects in injected lesions, leading to the release of tumour-derived antigens and systemic immune effects mediated by the induction of anti-tumour immunity, which is enhanced by the production of granulocyte macrophage colony-stimulating factor. Responses (which occur in >40% of stage IIIB-IVM1a patients) are often durable (>50% last ≥6 months) and occur in injected and uninjected lesions (in stage IIIB-IVM1c patients, 64%/34% of evaluable injected/uninjected non-visceral lesions, respectively, decreased in size by ≥50%). As with other immunotherapies, responses may be delayed or can arise after pseudoprogression. The pattern of treatment-emergent adverse events is distinct, being mostly grade 1/2, easy to manage, and rarely leading to treatment discontinuation. Systemic therapy represents the backbone of care for many metastatic melanoma patients. Nonetheless, the potential for durable locoregional control with a locally injected agent may make talimogene laherparepvec suitable for selected patients with stage IIIB/C disease, for whom surgery is not possible (e.g. with in-transit metastases, multiple melanoma lesions at different body sites, or those relapsing rapidly after repeated rounds of surgery) and slowly progressing disease. Here, we discuss which patients could be suitable for talimogene laherparepvec monotherapy based on the European indication, review the patterns/timing of response, and discuss the incidence/management of adverse events. Its potential use combined with immune checkpoint inhibitors is also discussed.

5 Review Cutaneous toxicities of new treatments for melanoma. 2018

Boada, A / Carrera, C / Segura, S / Collgros, H / Pasquali, P / Bodet, D / Puig, S / Malvehy, J. ·Dermatology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Crta/Canyet s/n., Badalona, 08016, Barcelona, Spain. aramboada@gmail.com. · Melanoma Unit, Dermatology Department, Hospital Clinic, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), CIBERER, Universitat de Barcelona, Barcelona, Spain. · Dermatology Department, Hospital del Mar, Parc de Salut Mar, Fundació Institut Mar d'Investigacions Mèdiques, Barcelona, Spain. · Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sidney, Australia. · Dermatology Department, Pius Hospital Valls, Institut d'Investigació Sanitària Pere Virgili Valls, Tarragona, Spain. · Dermatology Department, Hospital Universitari Vall d'Hebron, VHIR, Barcelona, Spain. ·Clin Transl Oncol · Pubmed #29799097.

ABSTRACT: New drugs against advanced melanoma have emerged during last decade. Target therapy and immunotherapy have changed the management of patients with metastatic disease. Along with its generalized use, drug toxicities have appeared and the skin is the target organ of a significant part of them. This revision summarizes the most common side effects and consensus management to improve the compliance of therapies and patients' quality of life. Among the BRAF inhibitors, main cutaneous side effects are photosensitivity, plantar hyperkeratosis, and the appearance of verrucal keratosis or squamous cell carcinoma. Special attention must be paid to the development of new primary melanomas or changes on nevi during BRAF inhibitor therapy. The most common cutaneous side effects of immunotherapy are rash, pruritus, and vitiligo. It remains controversial the possible role of these toxicities as markers of response to therapy.

6 Review A practical guide to the handling and administration of talimogene laherparepvec in Europe. 2017

Harrington, Kevin J / Michielin, Olivier / Malvehy, Josep / Pezzani Grüter, Isabella / Grove, Lorna / Frauchiger, Anna Lisa / Dummer, Reinhard. ·NIHR Biomedical Research Centre, The Institute of Cancer Research/The Royal Marsden Hospital, London, UK. · Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. · Hospital Clinic de Barcelona, IDIBAPS, CIBER de enfermedades raras, Barcelona, Spain. · FIS del Instituto de Salud Carlos III, Madrid, Spain. · Department of Research and Development, Amgen Switzerland AG, Zug, Switzerland. · Head and Neck Unit, The Royal Marsden Hospital, London, UK. · Skin Cancer Centre/Dermatology Clinic, Universitätsspital Zürich, Zurich, Switzerland. ·Onco Targets Ther · Pubmed #28814886.

ABSTRACT: Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene laherparepvec is a genetically modified viral therapy, and its handling needs special attention due to its deep freeze, cold-chain requirements, its potential for viral shedding, and its administration by direct intralesional injection. This review provides a practical overview of handling, storage, and administration procedures for this agent in Europe. Talimogene laherparepvec vials should be transported/stored frozen at a temperature of -90°C to -70°C, and once thawed, vials must not be refrozen. Universal precautions for preparation, administration, and handling should be followed to avoid accidental exposure. Health care providers should wear personal protective equipment, and materials that come into contact with talimogene laherparepvec should be disposed of in accordance with local institutional procedures. Individuals who are immunocompromised or pregnant should not prepare or administer this agent. Talimogene laherparepvec is administered by intralesional injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound. Treatment should be continued for ≥6 months. As with other immunotherapies, patients may experience an increase in the size of existing lesion(s) or the appearance of new lesions (ie, progression) prior to achieving a response ("pseudo-progression"). As several health care professionals (eg, physicians [dermatologists, surgeons, oncologists, radiologists], pharmacists, nurses) are involved in different stages of the process, there is a need for good interdisciplinary collaboration when using talimogene laherparepvec. Although there are specific requirements for this agent's storage, handling, administration, and disposal, these can be effectively managed in a real-world clinical setting through the implementation of training programs and straightforward standard operating procedures.

7 Review Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe. 2016

Harries, Mark / Malvehy, Josep / Lebbe, Céleste / Heron, Louise / Amelio, Justyna / Szabo, Zsolt / Schadendorf, Dirk. ·Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UK. Electronic address: Mark.Harries@gstt.nhs.uk. · Servicio de Dermatología, Hospital Clínic de Barcelona, Catalonia, Spain. · Assistance Publique - Hôpitaux de Paris (AP-HP) Hôpital Saint-Louis, Dermatology Department Université Paris-Diderot, Sorbonne Paris Cité, INSERM UMR-S 976, Paris, France. · Adelphi Values, Bollington, UK. · Amgen Ltd., Uxbridge, London UK. · Amgen GmbH, Zug, Switzerland. · Klinik für Dermatologie, Universitätsklinikum Essen, Essen, Germany. ·Eur J Cancer · Pubmed #27118416.

ABSTRACT: AIMS AND BACKGROUND: With the recent emergence of immunotherapies and novel targeted treatments for advanced and metastatic melanoma such as selective B-Raf inhibitors and checkpoint inhibitors, the treatment landscape in Europe has changed considerably. The aim of this review was to provide an overview of current treatment pathways in Europe for the treatment of advanced melanoma, unresectable stage III-IV. METHODS: A literature search of four databases was conducted to identify publications reporting on the treatment patterns of advanced and metastatic melanoma (stage III-IV) in European populations. RESULTS: Seven full-text publications and two conference abstracts reported on observational studies of melanoma treatment practices in France, Italy and the United Kingdom. Treatment patterns were identified for two time periods: 2005-2009 and 2011-2012. Common treatments reported for both periods included chemotherapy with dacarbazine, fotemustine or temozolomide. The main differences between the two periods were the introduction and prescription of immunotherapy ipilimumab and targeted therapy vemurafenib between 2011 and 2012. Across the three countries studied, the types of treatments prescribed between 2005 and 2009 were relatively similar, however, with noticeable differences in the frequency and priority of administration. CONCLUSION: Treatment practices for advanced melanoma vary markedly across different European countries and continue to evolve with the introduction of new therapies. The results of this review highlight a considerable evidence gap with regards to recent treatment patterns for advanced melanoma in Europe, especially post-2011 after the introduction of novel therapeutic agents, and more recently with the introduction of programmed cell death 1 inhibitors.

8 Review Standardization of terminology in dermoscopy/dermatoscopy: Results of the third consensus conference of the International Society of Dermoscopy. 2016

Kittler, Harald / Marghoob, Ashfaq A / Argenziano, Giuseppe / Carrera, Cristina / Curiel-Lewandrowski, Clara / Hofmann-Wellenhof, Rainer / Malvehy, Josep / Menzies, Scott / Puig, Susana / Rabinovitz, Harold / Stolz, Wilhelm / Saida, Toshiaki / Soyer, H Peter / Siegel, Eliot / Stoecker, William V / Scope, Alon / Tanaka, Masaru / Thomas, Luc / Tschandl, Philipp / Zalaudek, Iris / Halpern, Allan. ·Department of Dermatology, Medical University of Vienna, Vienna, Austria. Electronic address: harald.kittler@meduniwien.ac.at. · Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York. · Dermatology and Skin Cancer Unit, Arcispedale Santa Maria Nuova, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy. · Melanoma Unit, Department of Dermatology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER ER), Instituto de Salud Carlos III, Barcelona, Spain. · University of Arizona Cancer Center, Tucson, Arizona. · Department of Dermatology and Venerology, Nonmelanoma Skin Cancer Unit, Medical University of Graz, Graz, Austria. · Sydney Melanoma Diagnostic Center, Sydney Cancer Center, Royal Prince Alfred Hospital, Camperdown, Australia. · Skin and Cancer Associates, Plantation, Florida. · Department of Dermatology, Klinikum München, Munich, Germany. · Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan. · Dermatology Research Center, University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia. · University of Maryland Medical Center, Baltimore Department of Veterans Affairs Medical Center, Baltimore, Maryland. · Department of Dermatology, University of Missouri Health Sciences Center, Columbia, Missouri. · Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Dermatology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. · Department of Dermatology, Keio University, Tokyo, Japan. · Service de Dermatologie, Center Hospitalier Universitaire de Lyon, Lyon, France. · Department of Dermatology, Medical University of Vienna, Vienna, Austria. ·J Am Acad Dermatol · Pubmed #26896294.

ABSTRACT: BACKGROUND: Evolving dermoscopic terminology motivated us to initiate a new consensus. OBJECTIVE: We sought to establish a dictionary of standardized terms. METHODS: We reviewed the medical literature, conducted a survey, and convened a discussion among experts. RESULTS: Two competitive terminologies exist, a more metaphoric terminology that includes numerous terms and a descriptive terminology based on 5 basic terms. In a survey among members of the International Society of Dermoscopy (IDS) 23.5% (n = 201) participants preferentially use descriptive terminology, 20.1% (n = 172) use metaphoric terminology, and 484 (56.5%) use both. More participants who had been initially trained by metaphoric terminology prefer using descriptive terminology than vice versa (9.7% vs 2.6%, P < .001). Most new terms that were published since the last consensus conference in 2003 were unknown to the majority of the participants. There was uniform consensus that both terminologies are suitable, that metaphoric terms need definitions, that synonyms should be avoided, and that the creation of new metaphoric terms should be discouraged. The expert panel proposed a dictionary of standardized terms taking account of metaphoric and descriptive terms. LIMITATIONS: A consensus seeks a workable compromise but does not guarantee its implementation. CONCLUSION: The new consensus provides a revised framework of standardized terms to enhance the consistent use of dermoscopic terminology.

9 Review Methods of Melanoma Detection. 2016

Leachman, Sancy A / Cassidy, Pamela B / Chen, Suephy C / Curiel, Clara / Geller, Alan / Gareau, Daniel / Pellacani, Giovanni / Grichnik, James M / Malvehy, Josep / North, Jeffrey / Jacques, Steven L / Petrie, Tracy / Puig, Susana / Swetter, Susan M / Tofte, Susan / Weinstock, Martin A. ·Department of Dermatology and Knight Cancer Institute, Oregon Health and Science University, 3303 SW Bond Avenue, CH16D, Portland, OR, 97239, USA. leachmas@ohsu.edu. · Department of Dermatology and Knight Cancer Institute, Oregon Health and Science University, 3125 SW Sam Jackson Park Road, L468R, Portland, OR, 97239, USA. cassidyp@ohsu.edu. · Department of Dermatology, Emory University School of Medicine, 1525 Clifton Road NE, 1st Floor, Atlanta, GA, 30322, USA. schen2@emory.edu. · Department of Dermatology and Arizona Cancer Center, University of Arizona, 1515 N Campbell Avenue, Tucson, AZ, 85721, USA. ccuriel@email.arizona.edu. · Department of Dermatology, Harvard School of Public Health and Massachusetts General Hospital, Landmark Center, 401 Park Drive, 3rd Floor East, Boston, MA, 02215, USA. ageller@hsph.harvard.edu. · Laboratory of Investigative Dermatology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA. daniel.gareau@rockefeller.edu. · Department of Dermatology, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy. giovanni.pellacani@unimore.it. · Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Room 912, BRB (R-125), 1501 NW 10th Avenue, Miami, FL, 33136, USA. grichnik@miami.edu. · Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Villarroel 170, 08036, Barcelona, Spain. jmalvehy@clinic.ub.es. · University of California, San Francisco, 1701 Divisadero Street, Suite 280, San Francisco, CA, 94115, USA. jeffrey.north@ucsf.edu. · Department of Biomedical Engineering and Dermatology, Oregon Health and Science University, 3303 SW Bond Avenue, CH13B, Portland, OR, 97239, USA. jacquess@ohsu.edu. · Department of Biomedical Engineering, Oregon Health and Science University, 3303 SW Bond Avenue, CH13B, Portland, OR, 97239, USA. petrie@ohsu.edu. · Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Villarroel 170, 08036, Barcelona, Spain. spuig@clinic.ub.es. · Department of Dermatology/Cutaneous Oncology, Stanford University, 900 Blake Wilbur Drive, W3045, Stanford, CA, 94305, USA. sswetter@stanford.edu. · Department of Dermatology, Oregon Health and Science University, 3303 SW Bond Avenue, CH16D, Portland, OR, 97239, USA. toftes@ohsu.edu. · Departments of Dermatology and Epidemiology, Brown University, V A Medical Center 111D, 830 Chalkstone Avenue, Providence, RI, 02908, USA. maw@brown.edu. ·Cancer Treat Res · Pubmed #26601859.

ABSTRACT: Detection and removal of melanoma, before it has metastasized, dramatically improves prognosis and survival. The purpose of this chapter is to (1) summarize current methods of melanoma detection and (2) review state-of-the-art detection methods and technologies that have the potential to reduce melanoma mortality. Current strategies for the detection of melanoma range from population-based educational campaigns and screening to the use of algorithm-driven imaging technologies and performance of assays that identify markers of transformation. This chapter will begin by describing state-of-the-art methods for educating and increasing awareness of at-risk individuals and for performing comprehensive screening examinations. Standard and advanced photographic methods designed to improve reliability and reproducibility of the clinical examination will also be reviewed. Devices that magnify and/or enhance malignant features of individual melanocytic lesions (and algorithms that are available to interpret the results obtained from these devices) will be compared and contrasted. In vivo confocal microscopy and other cellular-level in vivo technologies will be compared to traditional tissue biopsy, and the role of a noninvasive "optical biopsy" in the clinical setting will be discussed. Finally, cellular and molecular methods that have been applied to the diagnosis of melanoma, such as comparative genomic hybridization (CGH), fluorescent in situ hybridization (FISH), and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), will be discussed.

10 Review Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma. 2015

Berrocal, Alfonso / Espinosa, Enrique / Marín, Severiano / Malvehy, Josep / Moreno, David / Lozano, Maria Dolores / Martin-Algarra, Salvador / Lopez, Jose Antonio / Conill, Carlos / Rodriguez-Peralto, Jose Luis. ·Department of Oncology. · Service of Oncology, Hospital La Paz, Madrid, Spain. · Plastic Surgery, Consorcio Hospital General Universitario, Avda, Tres Cruces, 2, 46014 Valencia, Spain. · Dermatology Department, Melanoma Unit, Hospital Clinic, Barcelona, Spain. · Dermatology Unit, Hospital Universitario Virgen Macarena, Seville, Spain. · Department of Pathology. · Department of Oncology, Clinica Universitaria de Navarra, Pamplona, Spain. · Department of Radiation Oncology, Hospital Clinic, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain. · Department of Pathology, Hospital 12 de Octubre, Madrid, Spain. ·Eur J Dermatol · Pubmed #26693633.

ABSTRACT: Advanced melanoma is a relatively uncommon condition whose therapeutic management has undergone major changes over the past four years. The present article aims to establish recommendations for the management of these patients based on the best available evidence reached by consensus of a group of professionals familiar in the treatment of these patients. These professionals, belonging to Spanish Multidisciplinary Melanoma Group, reviewed the diagnostic process and the incorporation of new techniques of molecular diagnosis of advanced disease; treatment and monitoring of stage III both as adjuvant locoregional treatments have been addressed, as well as new therapies for stage IV. We have reviewed the palliative treatment alternatives for disseminated disease, such as surgery, radiotherapy or non-cytotoxic systemic treatments. Finally, we have also reviewed the most relevant toxicities of new drugs and their management in clinical practice.

11 Review Update in genetic susceptibility in melanoma. 2015

Potrony, Miriam / Badenas, Celia / Aguilera, Paula / Puig-Butille, Joan Anton / Carrera, Cristina / Malvehy, Josep / Puig, Susana. ·1 Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain ; 2 Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Valencia, Spain ; 3 Molecular Biology and Genetics Department, Melanoma Unit, Hospital Clínic de Barcelona, Barcelona, Spain. ·Ann Transl Med · Pubmed #26488006.

ABSTRACT: Melanoma is the most deadly of the common skin cancers and its incidence is rapidly increasing. Approximately 10% of cases occur in a familial context. To date, cyclin-dependent kinase inhibitor 2A (CDKN2A), which was identified as the first melanoma susceptibility gene more than 20 years ago, is the main high-risk gene for melanoma. A few years later cyclin-dependent kinase 4 (CDK4) was also identified as a melanoma susceptibility gene. The technologic advances have allowed the identification of new genes involved in melanoma susceptibility: Breast cancer 1 (BRCA1) associated protein 1 (BAP1), CXC genes, telomerase reverse transcriptase (TERT), protection of telomeres 1 (POT1), ACD and TERF2IP, the latter four being involved in telomere maintenance. Furthermore variants in melanocortin 1 receptor (MC1R) and microphthalmia-associated transcription factor (MITF) give a moderately increased risk to develop melanoma. Melanoma genetic counseling is offered to families in order to better understand the disease and the genetic susceptibility of developing it. Genetic counseling often implies genetic testing, although patients can benefit from genetic counseling even when they do not fulfill the criteria for these tests. Genetic testing for melanoma predisposition mutations can be used in clinical practice under adequate selection criteria and giving a valid test interpretation and genetic counseling to the individual.

12 Review Monitoring patients with multiple nevi. 2013

Puig, Susana / Malvehy, Josep. ·Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Villarroel 170, Barcelona 08036, Spain. ·Dermatol Clin · Pubmed #24075545.

ABSTRACT: Early recognition is the most effective intervention to improve melanoma mortality. Early diagnosis of melanoma in atypical mole syndrome patients, however, may be challenging. Skin self-examination and periodic physician-based total-body skin examinations are recommended in atypical mole patients but dermoscopy, total-body photography, and digital dermatoscopy have been proved to improve accuracy in early detection of melanoma in these high-risk patients. Digital follow-up in atypical mole syndrome patients allows detection of new lesions and changes in preexisting lesions.

13 Review A clinico-dermoscopic approach for skin cancer screening: recommendations involving a survey of the International Dermoscopy Society. 2013

Argenziano, Giuseppe / Giacomel, Jason / Zalaudek, Iris / Blum, Andreas / Braun, Ralph P / Cabo, Horacio / Halpern, Allan / Hofmann-Wellenhof, Rainer / Malvehy, Josep / Marghoob, Ashfaq A / Menzies, Scott / Moscarella, Elvira / Pellacani, Giovanni / Puig, Susana / Rabinovitz, Harold / Saida, Toshiaki / Seidenari, Stefania / Soyer, H Peter / Stolz, Wilhelm / Thomas, Luc / Kittler, Harald. ·Dermatology and Skin Cancer Unit, Arcispedale Santa Maria Nuova IRCCS, Viale Risorgimento 80, Reggio Emilia 42100, Italy. Electronic address: g.argenziano@gmail.com. ·Dermatol Clin · Pubmed #24075542.

ABSTRACT: Dermoscopy is useful for skin cancer screening, but a detailed approach is required that integrates this tool into a rational clinical work flow. To investigate clinician perceptions and behavior in approaching patients with skin tumors, a survey was launched by electronic mail through the International Dermoscopy Society. After 4 months, the responses were analyzed and significant findings calculated. Considering the current approach of study participants in examining patients for skin cancer, an up-to-date system of triage is presented in this review, which aims to promote an improved diagnostic accuracy and more timely management of skin malignancy.

14 Review Dermoscopy for the pediatric dermatologist part III: dermoscopy of melanocytic lesions. 2013

Haliasos, Elena C / Kerner, Miryam / Jaimes, Natalia / Zalaudek, Iris / Malvehy, Josep / Hofmann-Wellenhof, Rainer / Braun, Ralph P / Marghoob, Ashfaq A. ·Department of Dermatology, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA. ·Pediatr Dermatol · Pubmed #23252411.

ABSTRACT: Melanocytic nevi encompass a variety of lesions, including blue, Spitz, congenital, and acquired nevi. These nevi can occasionally manifest clinical morphologies resembling melanoma, and the presence of such nevi in children can elicit anxiety in patients, parents, and clinicians. Dermoscopy has been shown to increase the diagnostic accuracy for melanoma and to help differentiate melanoma from nevi, ultimately aiding in the decision-making process as to whether to perform a biopsy. Dermoscopy is the perfect instrument to use during the evaluation of pigmented skin lesions in children because it is painless and provides important information for the clinician that can assist in formulating appropriate management decisions. This review highlights the most common benign dermoscopic patterns encountered in nevi and discuss the 10 most common dermoscopic structures seen in melanomas. Lesions manifesting a benign dermoscopic pattern and lacking any melanoma-specific structures do not need to be excised and can safely be monitored. In contrast, melanomas will invariably deviate from the benign nevus patterns and will usually manifest at least 1 of the 10 melanoma-specific structures: atypical network, negative network, streaks, crystalline structures, atypical dots and globules, irregular blotch, blue-white veil, regression structures, peripheral brown structureless areas, and atypical vessels. It is important to be cognizant of the fact that melanomas in childhood usually do not manifest the clinical ABCD features. Instead, they are often symmetric, amelanotic, nodular lesions. Although the clinical appearance may not be alarming, with dermoscopy they will invariably manifest at least one melanoma-specific structure, the most common being atypical vascular structures and crystalline structures.

15 Review Dermoscopic criteria and melanocytic lesions. 2012

Roldán-Marín, R / Puig, S / Malvehy, J. ·Diagnosis Dermatologica, Barcelona, Spain. ·G Ital Dermatol Venereol · Pubmed #22481578.

ABSTRACT: Dermoscopy is a noninvasive, in vivo method for the early diagnosis of malignant melanoma and the differential diagnosis of pigmented lesions of the skin. By allowing visualization of sub-macroscopic pigmented structures that correlate with specific underlying histopathologic structures, dermoscopy provides a more powerful tool than the naked-eye examination for clinicians to determine the need to excise a lesion. This article reviews the principles of dermoscopy, the most common dermoscopic patterns associated with nevi and melanoma, and the factors influencing the nevus pattern in a given individual.

16 Review Dermoscopic criteria and basal cell carcinoma. 2012

Puig, S / Cecilia, N / Malvehy, J. ·Melanoma Unit, Dermatology Department, Barcelona Clinical Hospital, IDIBAPS, Barcelona, Spain. susipuig@gmail.com ·G Ital Dermatol Venereol · Pubmed #22481576.

ABSTRACT: Basal cell carcinoma (BCC) is the most frequent of all skin cancers in the white population. Dermoscopy is a method that improves diagnosis in pigmented and non-pigmented skin lesions, allowing early diagnosis, especially of incipient lesions. The classical dermoscopy algorithm for the diagnosis of BCC includes lack of pigment network and the presence of at least one of the following criteria: ulceration, maple-leaf like structure, blue-gray globules, blue-ovoid nests, arborizing vessels and spoke-wheel structures. The non-classical dermoscopic features of BCC include some criteria more frequently seen in superficial BCC such as pink-white areas, concentric structures, multiple erosions, multiple in-focus blue-gray dots and fine vessels. Recently, the dermoscopy of Fibroepithelioma of Pinkus has also been described with the presence of fine arborizing vessels, white streaks and gray-brown structureless areas. Some dermoscopic structures also present in BCC are just visible with polarized dermoscopy such as white shiny streaks or Chrysalides and Rosetas. Improved knowledge of all these criteria may avoid some diagnostic pitfalls and improve the early recognition of BCCs.

17 Review [Melanocytic nevi, melanoma, and pregnancy]. 2011

Borges, V / Puig, S / Malvehy, J. ·Unidad de Melanoma, Servicio de Dermatología, Hospital Clínic, Barcelona, Spain. valborges@hotmail.com ·Actas Dermosifiliogr · Pubmed #21530926.

ABSTRACT: Malignant melanoma is among the malignant tumors whose incidence has risen markedly in recent decades. For many years the medical community debated the potential adverse effects of female hormones (whether of exogenous or pregnancy-related endogenous origin), on melanocytic nevi and malignant melanoma. Given that women have been delaying pregnancy until their thirties or forties and that the incidence of malignant melanoma increases in those decades, the likelihood of this tumor developing during pregnancy has increased. Recent clinical and experimental evidence has suggested that pregnancy does not affect prognosis in malignant melanoma and that it does not seem to lead to significant changes in nevi. This review examines the relationship between malignant melanoma and hormonal and reproductive factors. Evidence was located by MEDLINE search (in PubMed and Ovid) for articles in English and Spanish for the period from 1966 to March 2010; additional sources were found through the reference lists of the identified articles.

18 Review Dermoscopy of benign and malignant neoplasms in the pediatric population. 2010

Haliasos, Helen C / Zalaudek, Iris / Malvehy, Josep / Lanschuetzer, Christoph / Hinter, Helmut / Hofmann-Wellenhof, Rainer / Braun, Ralph / Marghoob, Ashfaq A. ·Division of Dermatology, Medical University of Graz, Graz, Austria. ·Semin Cutan Med Surg · Pubmed #21277535.

ABSTRACT: Dermoscopy is a noninvasive technique that enables visualization of subsurface colors and structures within the skin that are imperceptible to the naked eye. The dermatoscope allows the physician to examine both the macroscopic and microscopic primary morphology of skin lesions, identify subtle clinical clues, confirm naked-eye clinical diagnoses, and monitor treatment progress while posing little threat to the young patient. Dermoscopic findings have been formulated into diagnostic criteria that assist experienced clinicians in differentiating benign and malignant neoplasms. In this review, clinical morphology of melanocytic nevi and melanoma in the pediatric population is examined and the relevant dermoscopic findings and histopathologic correlates that aid in the diagnosis and management of these lesions are described.

19 Clinical Trial Should immediate lymphadenectomy be discontinued in patients with metastasis of a melanoma in the sentinel lymph node? Report of the results of the Multicenter Selective Lymphadenectomy Trial-II. 2018

Moreno-Ramírez, David / Vidal-Sicart, Sergi / Puig, Susana / Malvehy, Josep. ·Unidad de Melanoma, Servicio de Dermatología, Hospital Clínic, Barcelona, España. Electronic address: dmoreno@e-derma.org. · Servicio de Medicina Nuclear, Hospital Clínic, Barcelona, España. · Unidad de Melanoma, Servicio de Dermatología, Hospital Clínic, Barcelona, España. ·Med Clin (Barc) · Pubmed #29089120.

ABSTRACT: -- No abstract --

20 Clinical Trial Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. 2017

Ribas, Antoni / Dummer, Reinhard / Puzanov, Igor / VanderWalde, Ari / Andtbacka, Robert H I / Michielin, Olivier / Olszanski, Anthony J / Malvehy, Josep / Cebon, Jonathan / Fernandez, Eugenio / Kirkwood, John M / Gajewski, Thomas F / Chen, Lisa / Gorski, Kevin S / Anderson, Abraham A / Diede, Scott J / Lassman, Michael E / Gansert, Jennifer / Hodi, F Stephen / Long, Georgina V. ·University of California at Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address: aribas@mednet.ucla.edu. · University Hospital of Zurich, Zurich, Switzerland. · Roswell Park Cancer Institute, Buffalo, NY, USA. · The West Clinic, Memphis, TN, USA. · University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA. · Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. · Fox Chase Cancer Center, Philadelphia, PA, USA. · Hospital Clinic i Provincial de Barcelona, Barcelona, Spain. · Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, LaTrobe University, Heidelberg, VIC, Australia. · Hopitaux Universitaires de Genève, Geneva, Switzerland. · University of Pittsburgh Cancer Institute and Hillman UPMC Cancer Center, Pittsburgh, PA, USA. · The University of Chicago School of Medicine, Chicago, IL, USA. · Amgen Inc., Thousand Oaks, CA, USA. · Amgen Inc., South San Francisco, CA, USA. · Merck & Co., Inc., Kenilworth, NJ, USA. · Dana-Farber Cancer Institute, Boston, MA, USA. · Melanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. ·Cell · Pubmed #28886381.

ABSTRACT: Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurred. Confirmed objective response rate was 62%, with a complete response rate of 33% per immune-related response criteria. Patients who responded to combination therapy had increased CD8

21 Article Sutton Naevi as Melanoma Simulators: Can Confocal Microscopy Help in the Diagnosis? 2020

Brugués, Albert / Ribero, Simone / Martins da Silva, Vanessa / Aguilera, Paula / Garcia, Adriana P / Alós, Llucia / Malvehy, Josep / Puig, Susana / Carrera, Cristina. ·Dermatology Department, Hospital Clínic and Melanoma Group IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), ES-08036 Barcelona, Spain. ·Acta Derm Venereol · Pubmed #32318743.

ABSTRACT: Sutton naevi can sometimes present a challenging appearance with atypical presentation, also by dermoscopy. Reflectance confocal microscopy could help in making a diagnosis. This study prospectively collected two groups of Sutton nevi: the first one was composed by typical white halo naevi monitored for one year (13, 23%) and the second one was made up of atypical lesions excised in order to rule out melanoma, which were histologically diagnosed as Sutton naevi (21, 37%). These two groups of Sutton naevi were compared to a retrospectively collected cohort of thin melanomas with histologic regression features (23, 40%). On dermoscopy, atypical Sutton naevi and melanomas were indistinguishable. Reflectance confocal microscopy demonstrated significant differences at the dermo-epidermal junction: marked dermo-epidermal junction thickening and non-edged papilla were associated with melanoma, while the presence of nests was associated with Sutton naevi. However, reflectance confocal microscopy also detected marked intraepidermal pagetoid cells in Sutton naevi that were a combination of MelanA+ and CD1a+ cells. Sutton naevi can simulate melanoma, under both dermoscopy and reflectance confocal microscopy. Nevertheless, relevant confocal dermo-epidermal junction features and the clinical scenario can be helpful to make a final diagnosis, especially in those situations where melanoma must be ruled out.

22 Article Age as a prognostic factor in thick and ultrathick melanomas without lymph node metastasis. 2020

Boada, A / Tejera-Vaquerizo, A / Ribero, S / Puig, S / Moreno-Ramírez, D / Osella-Abate, S / Cassoni, P / Malvehy, J / Podlipnik, S / Requena, C / Manrique-Silva, E / Rios Martin, J J / Ferrándiz, C / Nagore, E / Anonymous5991157. ·Dermatology Department. Hospital, Universitari Germans Trial i Pujol. Fundació Institut d'Investigació Germans Trias i Pujol. Badalona, Departament de Medicina, Universitat Autònoma de Barcelona, Spain. · Dermatology Department, Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba, Spain. · Medical Sciences Department. Section of Dermatology, University of Turin, Turin, Italy. · Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Barcelona, Spain. · Melanoma Unit. Medical-&-Surgical Dermatology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain. · Section of Surgical Pathology, Medical Science Department, University of Turin, Turin, Italy. · Melanoma Unit. Dermatology Department. Hospital Clinic. Universitat de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. · Dermatology Department, Instituto Valenciano de Oncología, Valencia, Spain. · Pathology Department. Hospital, Universitario Virgen Macarena, Sevilla, Spain. ·J Eur Acad Dermatol Venereol · Pubmed #32259328.

ABSTRACT: The presence of regional metastasis is a predictor of worse survival in thick melanoma

23 Article Machine Learning in Melanoma Diagnosis. Limitations About to be Overcome. 2020

González-Cruz, C / Jofre, M A / Podlipnik, S / Combalia, M / Gareau, D / Gamboa, M / Vallone, M G / Faride Barragán-Estudillo, Z / Tamez-Peña, A L / Montoya, J / América Jesús-Silva, M / Carrera, C / Malvehy, J / Puig, S. ·Servicio de Dermatología, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Dermatología, Hospital Clínic de Barcelona, Barcelona, España; Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, España. · Laboratory of Investigative Dermatology, The Rockefeller University, Nueva York, EE. UU. · Servicio de Dermatología, Hospital Clínic de Barcelona, Barcelona, España; Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, España; CIBER en Enfermedades raras, Instituto de Salud Carlos III, Barcelona, España. · Servicio de Dermatología, Hospital Clínic de Barcelona, Barcelona, España; Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, España; CIBER en Enfermedades raras, Instituto de Salud Carlos III, Barcelona, España. Electronic address: susipuig@gmail.com. ·Actas Dermosifiliogr · Pubmed #32248945.

ABSTRACT: BACKGROUND: Automated image classification is a promising branch of machine learning (ML) useful for skin cancer diagnosis, but little has been determined about its limitations for general usability in current clinical practice. OBJECTIVE: To determine limitations in the selection of skin cancer images for ML analysis, particularly in melanoma. METHODS: Retrospective cohort study design, including 2,849 consecutive high-quality dermoscopy images of skin tumors from 2010 to 2014, for evaluation by a ML system. Each dermoscopy image was assorted according to its eligibility for ML analysis. RESULTS: Of the 2,849 images chosen from our database, 968 (34%) met the inclusion criteria for analysis by the ML system. Only 64.7% of nevi and 36.6% of melanoma met the inclusion criteria. Of the 528 melanomas, 335 (63.4%) were excluded. An absence of normal surrounding skin (40.5% of all melanomas from our database) and absence of pigmentation (14.2%) were the most common reasons for exclusion from ML analysis. DISCUSSION: Only 36.6% of our melanomas were admissible for analysis by state-of-the-art ML systems. We conclude that future ML systems should be trained on larger datasets which include relevant non-ideal images from lesions evaluated in real clinical practice. Fortunately, many of these limitations are being overcome by the scientific community as recent works show.

24 Article Microblotches on Dermoscopy of Melanocytic Lesions are Associated with Melanoma: A Cross-sectional Study. 2020

Lukoviek, Vania / Ferrera, Nuria / Podlipnik, Sebastian / Ertekin, Sümeyre Seda / Carrera, Cristina / Barreiro, Alicia / Chavez-Bourgeois, Marion / Perino, Francesca / Ortiz-Ruiz, Mauricio / Puig, Susana / Malvehy, Josep. ·Department of Dermatology, Melanoma Unit, Hospital Clínic of Barcelona, Barcelona, Spain. ·Acta Derm Venereol · Pubmed #32110813.

ABSTRACT: Numerous dermoscopic structures for the early detection of melanoma have been described. The aim of this study was to illustrate the characteristics of dermoscopic structures that are similar to blotches, but smaller (termed microblotches), and to evaluate their association with other well-known dermoscopic structures. A cross-sectional study design, including 165 dermoscopic images of melanoma was used to define microblotches, and 241 consecutive images of naevi from the HAM10000 database, were studied to evaluate the prevalence of this criterion in both groups. Microblotches were defined as sharply demarcated structures ≤1 mm, with geographical borders visible only with dermoscopy. Microblotches were present in 38.7% of the melanomas and 6.7% of the naevi. Moreover, microblotches were associated with an odds ratio (OR) of malignancy of 5.79, and were more frequent in invasive melanoma than in the in-situ subtype (OR 2.92). Histologically, they correspond to hyperpigmented parakeratosis or epidermal consumption. In conclusion, microblotches are related to melanomas. This finding could help dermatologists to differentiate between naevi and melanomas.

25 Article European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. 2020

Garbe, Claus / Amaral, Teresa / Peris, Ketty / Hauschild, Axel / Arenberger, Petr / Bastholt, Lars / Bataille, Veronique / Del Marmol, Veronique / Dréno, Brigitte / Fargnoli, Maria Concetta / Grob, Jean-Jacques / Höller, Christoph / Kaufmann, Roland / Lallas, Aimilios / Lebbé, Celeste / Malvehy, Josep / Middleton, Mark / Moreno-Ramirez, David / Pellacani, Giovanni / Saiag, Philippe / Stratigos, Alexander J / Vieira, Ricardo / Zalaudek, Iris / Eggermont, Alexander M M / Anonymous9471072. ·Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. Electronic address: claus.garbe@med.uni-tuebingen.de. · Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany; Portuguese Air Force Health Care Direction, Lisbon, Portugal. · Institute of Dermatology, Università Cattolica, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy. · Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany. · Department of Dermatovenerology, Third Faculty of Medicine, Charles University of Prague, Prague, Czech Republic. · Department of Oncology, Odense University Hospital, Denmark. · Twin Research and Genetic Epidemiology Unit, School of Basic & Medical Biosciences, King's College London, London, SE1 7EH, UK. · Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. · Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France. · Department of Dermatology, University of L'Aquila, Italy. · University Department of Dermatology, Marseille, France. · Department of Dermatology, Medical University of Vienna, Austria. · Department of Dermatology, Venerology and Allergology, Frankfurt University Hospital, Frankfurt, Germany. · First Department of Dermatology, Aristotle University, Thessaloniki, Greece. · APHP Department of Dermatology, INSERM U976, University Paris 7 Diderot, Saint-Louis University Hospital, Paris, France. · Melanoma Unit, Department of Dermatology, Hospital Clinic, IDIBAPS, Barcelona, Spain. · NIHR Biomedical Research Center, University of Oxford, UK. · Medical-&-Surgical Dermatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain. · Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy. · University Department of Dermatology, Université de Versailles-Saint Quentin en Yvelines, APHP, Boulogne, France. · 1st Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece. · Department of Dermatology and Venereology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal. · Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy. · Princess Máxima Center, 3584 CS, Utrecht, the Netherlands. ·Eur J Cancer · Pubmed #31928887.

ABSTRACT: Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.

Next